Humoral and T-cell responses to a third dose of BNT162b2 and mRNA-1273 COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study.
- Conditions
- Hematological diseases
- Registration Number
- JPRN-UMIN000046603
- Lead Sponsor
- Kobe City Medical Center General Hospital, Department of Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 68
Not provided
1) Patients who are judged inappropriate for participation in the study by the investigators 2) Patients who have previously received rituximab for non-hematological diseases (polyangiitis granulomatosa, microscopic polyangiitis, refractory nephrotic syndrome) 3) Patients with a history of COVID-19 4) Patients with autoimmune diseases other than chronic idiopathic thrombocytopenic purpura (systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, systemic scleroderma, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondyloarthritis and related diseases, vasculitis syndromes, inflammatory bowel disease, Guillain-Barre syndrome, and inflammatory bowel disease) Guillain-Barre syndrome, multiple sclerosis, neuromyelitis optica). 5) Patients who are unable to communicate with others
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method